Last updated on July 2020

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Brief description of study

The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recurrence.

Clinical Study Identifier: NCT04136353

Find a site near you

Start Over

Townsville Hospital

Townsville, Australia
  Connect »

Gosford Hospital

Gosford, Australia
  Connect »

Wollongong Hospital

Wollongong, Australia
  Connect »


Brisbane, Australia
  Connect »

Icon Cancer Centre

Southport, Australia
  Connect »

Box Hill Hospital

Box Hill, Australia
  Connect »

The Alfred Hospital

Melbourne, Australia
  Connect »

Sunshine Hospital

St Albans, Australia
  Connect »

Christchurch Hospital

Christchurch, New Zealand
  Connect »

Palmerston North Hospital

Palmerston North, New Zealand
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.